Current therapies for pulmonary hypertension (PH) include several classes of vasodilators, including prostacyclins, calcium channel blockers, PDE5 inhibitors, endothelin receptor antagonists (ETRA), and soluble guanylate cyclase stimulators, all of which are limited by systemic hypotension. Several agents including ETRA and prostacyclin have additional dose-limiting systemic side effects or toxicities. Moreover, many patients are unresponsive to these agents at diagnosis or during the course of therapy, due to advanced disease, progression, or drug tachyphylaxis. This virtual symposium, presented by Biochemical Pharmacology Discussion Group, will convene basic researchers, clinicians, and drug developers to discuss latest advances in the development of novel therapeutics that can overcome the limitations of current therapy for PH.
October 12, 2021